[Source: GLOBE NEWSWIRE] – Capstone Therapeutics today announced the presentation of pre-clinical data at theAmerican College of Surgeons 95th Annual Clinical Conference in Chicago, IL,demonstrating significant benefit of Chrysalin(R) (rusalatide acetate or TP508)in a model of acute heart disease and elevated cholesterol. The data, aspreviously announced and as originally published in April 2009, demonstrate thatChrysalin, administered following the onset of ischemia, showed a statisticallysignificant cardioprotective benefit in an elevated-cholesterol porcine model of acute myocardial infarction (AMI or heart attack).